TY - JOUR AU - Ungvári, Zoltán István AU - Fekete, Mónika AU - Varga, Péter AU - Munkácsy, Gyöngyi AU - Fekete, János Tibor AU - Lehoczki, Andrea Marianna AU - Buda, Annamaria AU - Kiss, Csaba AU - Ungvári, Anna Sára AU - Győrffy, Balázs TI - Exercise and survival benefit in cancer patients : evidence from a comprehensive meta-analysis JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01647-0 UR - https://m2.mtmt.hu/api/publication/36089230 ID - 36089230 N1 - * Megosztott szerzőség AB - Cancer remains a major global health challenge, and growing evidence suggests that physical activity is a key modifiable factor that may improve survival outcomes in cancer patients. However, a comprehensive, large-scale synthesis of the effects of post-diagnosis physical activity across multiple cancer types remains lacking. This meta-analysis aims to systematically evaluate the association between physical activity and survival in patients diagnosed with breast, lung, prostate, colorectal, and skin cancers. We conducted a comprehensive search in PubMed, Web of Science, Scopus, and Cochrane Library for studies on physical activity and cancer survival. Eligible studies (January 2000-November 2024) included adults (≥ 18 years) with breast, lung, prostate, colorectal, or skin cancer. Only prospective cohort and case-control studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for overall or cancer-specific mortality were included, with a minimum sample size of 100 and at least six months of follow-up. Meta-analysis was performed using metaanalysisonline.com, applying random-effects models and assessing heterogeneity via the I2 statistic. Sensitivity analyses and publication bias (Egger's test, funnel plots) were evaluated. The meta-analysis included 151 cohorts with almost 1.5 million cancer patients. Post-diagnosis physical activity was associated with significantly lower cancer-specific mortality across all five cancer types. The greatest benefit was observed in breast cancer, with a pooled hazard ratio (HR) of 0.69 (95% CI: 0.63-0.75), followed by prostate cancer (HR: 0.73, 95% CI: 0.62-0.87). Lung cancer patients who engaged in physical activity had a 24% lower risk of cancer-specific death (HR: 0.76, 95% CI: 0.69-0.84), while colorectal cancer patients experienced a similar benefit (HR: 0.71, 95% CI: 0.63-0.80). In skin cancer, physical activity was associated with a non-significant reduction in mortality (HR: 0.86, 95% CI: 0.71-1.05). These findings provide robust evidence supporting the survival benefits of post-diagnosis physical activity in cancer patients, particularly for breast, prostate, lung, and colorectal cancers. The results underscore the potential for incorporating structured physical activity interventions into oncological care to improve long-term patient outcomes. LA - English DB - MTMT ER - TY - JOUR AU - Ungvári, Zoltán István AU - Fekete, Mónika AU - Varga, Péter AU - Lehoczki, Andrea Marianna AU - Munkácsy, Gyöngyi AU - Fekete, János Tibor AU - Bianchini, Giampaolo AU - Ocana, Alberto AU - Buda, Annamaria AU - Ungvári, Anna Sára AU - Győrffy, Balázs TI - Association between red and processed meat consumption and colorectal cancer risk : a comprehensive meta-analysis of prospective studies JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01646-1 UR - https://m2.mtmt.hu/api/publication/36088936 ID - 36088936 N1 - * Megosztott szerzőség AB - Increasing evidence suggests that red and processed meat consumption may elevate the risk of colorectal cancer (CRC), yet the magnitude and consistency of this association remain debated. This meta-analysis aims to quantify the relationship between red and processed meat intake and the risk of CRC, colon cancer, and rectal cancer using the most comprehensive set of prospective studies to date. We conducted a comprehensive search in PubMed, Web of Science, Cochrane Library, Embase, and Google Scholar databases from 1990 to November 2024, to identify relevant prospective studies examining red, processed, and total meat consumption in relation to colorectal, colon, and rectal cancer risk. Hazard ratios (HR) and 95% confidence intervals (CI) were extracted for each study and pooled using a random-effects model to account for variability among studies. Statistical evaluation was executed using the online platform MetaAnalysisOnline.com. A total of 60 prospective studies were included. Red meat consumption was associated with a significantly increased risk of colon cancer (HR = 1.22, 95% CI 1.15-1.30), colorectal cancer (HR = 1.15, 95% CI 1.10-1.21), and rectal cancer (HR = 1.22, 95% CI 1.07-1.39). Processed meat consumption showed similar associations with increased risk for colon cancer (HR = 1.13, 95% CI 1.07-1.20), colorectal cancer (HR = 1.21, 95% CI 1.14-1.28), and rectal cancer (HR = 1.17, 95% CI 1.05-1.30). Total meat consumption also correlated with an elevated risk of colon cancer (HR = 1.22, 95% CI 1.11-1.35), colorectal cancer (HR = 1.17, 95% CI 1.12-1.22), and rectal cancer (HR = 1.28, 95% CI 1.10-1.48). This meta-analysis provides robust evidence that high consumption of red and processed meats is significantly associated with an increased risk of colorectal, colon, and rectal cancers. These findings reinforce current dietary recommendations advocating for the limitation of red and processed meat intake as part of cancer prevention strategies. LA - English DB - MTMT ER - TY - JOUR AU - Ungvári, Zoltán István AU - Fekete, Mónika AU - Lehoczki, Andrea Marianna AU - Munkácsy, Gyöngyi AU - Fekete, János Tibor AU - Zábó, Virág AU - Purebl, György AU - Varga, Péter AU - Ungvári, Anna Sára AU - Győrffy, Balázs TI - Sleep disorders increase the risk of dementia, Alzheimer’s disease, and cognitive decline : a meta-analysis JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01637-2 UR - https://m2.mtmt.hu/api/publication/36088767 ID - 36088767 N1 - * Megosztott szerzőség AB - Sleep disorders, particularly insomnia and obstructive sleep apnea, are increasingly implicated as significant contributors to cognitive decline, dementia, and neurodegenerative diseases such as Alzheimer’s disease (AD) and vascular cognitive impairment and dementia (VCID). However, the extent and specificity of these associations remain uncertain. This meta-analysis evaluates the impact of common sleep disorders on the risk of developing dementia and cognitive decline. A comprehensive search of the literature was conducted to identify prospective cohort studies assessing sleep disorders and dementia risk. Studies reporting risk estimates for dementia, AD, or cognitive decline associated with obstructive sleep apnea, insomnia, and other sleep disorders (e.g., restless legs syndrome, circadian rhythm sleep disorders, excessive daytime sleepiness) were included. Meta-analyses were performed using a random-effects model to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Thirty-nine cohort studies were included, with subgroup analyses showing significant associations between all-cause dementia and obstructive sleep apnea (HR 1.33, 95% CI 1.09–1.61), insomnia (HR 1.36, 95% CI 1.19–1.55), and other sleep disorders (HR 1.33, 95% CI 1.24–1.43). Obstructive sleep apnea increased the risk for AD (HR 1.45, 95% CI 1.24–1.69), though its association with vascular dementia did not reach statistical significance (HR 1.35, 95% CI 0.99–1.84). Insomnia was significantly associated with increased risk for both vascular dementia (HR 1.59, 95% CI 1.01–2.51) and AD (HR 1.49, 95% CI 1.27–1.74). This meta-analysis highlights the critical role of sleep disorders in dementia risk, emphasizing the need for early detection and management of sleep disturbances. Targeted interventions could play a pivotal role in reducing dementia risk, particularly among high-risk populations. LA - English DB - MTMT ER - TY - JOUR AU - Ungvári, Zoltán István AU - Fekete, Mónika AU - Fekete, János Tibor AU - Lehoczki, Andrea Marianna AU - Buda, Annamaria AU - Munkácsy, Gyöngyi AU - Varga, Péter AU - Ungvári, Anna Sára AU - Győrffy, Balázs TI - Treatment delay significantly increases mortality in colorectal cancer : a meta-analysis JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01648-z UR - https://m2.mtmt.hu/api/publication/36084206 ID - 36084206 N1 - * Megosztott szerzőség AB - Delaying the initiation of cancer treatment increases the risk of mortality, particularly in colorectal cancer (CRC), which is among the most common and deadliest malignancies. This study aims to explore the impact of treatment delays on mortality in CRC. A systematic literature search was conducted in PubMed, Web of Science, and Scopus for studies published between 2000 and 2025. Meta-analyses were performed using random-effects models with inverse variance method to calculate hazard ratios (HRs) for both overall and cancer-specific survival at 4-, 8-, and 12-week treatment delay intervals, with heterogeneity assessed through I2-statistics and publication bias evaluated using funnel plots and Egger's test. A total of 20 relevant studies were included in the meta-analysis. The analyses of all patients demonstrated a progressively increasing risk of 12-39% with longer treatment delays (4 weeks, HR = 1.12; 95% CI, 1.08-1.16; 8 weeks, HR = 1.24; 95% CI, 1.16-1.34; 12 weeks, HR = 1.39; 95% CI, 1.25-1.55). In particular, incrementally higher hazard ratios were observed for all-cause mortality at 4 weeks (HR = 1.14; 95% CI, 1.09-1.18), 8 weeks (HR = 1.29; 95% CI, 1.20-1.39), and 12 weeks (HR = 1.47; 95% CI, 1.31-1.64). In contrast, cancer-specific survival analysis showed a similar trend but did not reach statistical significance (4 weeks, HR = 1.07; 95% CI, 0.98-1.18; 8 weeks, HR = 1.15; 95% CI, 0.95-1.39; 12 weeks, HR = 1.23; 95% CI, 0.93-1.63). Treatment delays in colorectal cancer patients were associated with progressively worsening overall survival, with each 4-week delay increment leading to a substantially higher mortality risk. This study suggests that timely treatment initiation should be prioritized in clinical practice, as these efforts can lead to substantial improvements in survival rates. LA - English DB - MTMT ER - TY - JOUR AU - Lehoczki, Andrea Marianna AU - Menyhart, Otilia AU - Andrikovics, Hajnalka AU - Fekete, Mónika AU - Kiss, Csaba AU - Mikala, Gábor AU - Ungvári, Zoltán István AU - Győrffy, Balázs TI - Prognostic impact of a senescence gene signature in multiple myeloma. JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01622-9 UR - https://m2.mtmt.hu/api/publication/36067301 ID - 36067301 N1 - * Megosztott szerzőség AB - Multiple myeloma (MM), an incurable malignancy of plasma cells, is predominantly an age-related disease, with the majority of cases occurring in patients over the age of 60. Cellular senescence, a fundamental biological process underlying aging, has been increasingly recognized for its critical role in developing age-related malignancies. In this study, we aimed to investigate the prognostic significance of genes implicated in the molecular mechanisms of senescence within a large cohort of MM patients. Gene expression and clinical data from 1416 MM patients were obtained from four GEO datasets (GSE24080, GSE4204, GSE57317, and GSE9782) and integrated into a unified database. The raw data were processed using MAS5 normalization, scaling adjustments, and JetSet probe selection to ensure cross-platform comparability. A curated set of senescence-associated genes, the SenMayo gene signature, was employed for subsequent analyses. The final gene signature was computed as a weighted mean expression of 122 senescence-associated genes, with weights derived from univariate hazard ratios. Prognostic significance was evaluated using Cox regression, Kaplan-Meier survival analysis, and multivariate models incorporating clinical parameters such as gender, isotype, and molecular subtypes. False discovery rate (FDR) correction was applied to ensure the statistical robustness of findings. The weighted SenMayo gene signature strongly correlated with overall survival in MM patients (HR = 0.6, 95% CI = 0.47-0.76, p = 1.7e-05). The 75th percent probability of survival was reached at 36.1 months in the low-expression patient group, compared to 57 months in the high-expression group. Independent validation in datasets with sufficient patient numbers confirmed the prognostic value of the SenMayo signature (GSE4204: HR = 0.58, 95% CI = 0.39-0.88, p = 0.0089; GSE24080: HR = 0.61, 95% CI = 0.45-0.83, p = 0.0012; GSE57317: HR = 0.25, 95% CI = 0.08-0.77, p = 0.0095). Multivariate analyses further established the SenMayo signature as an independent prognostic factor, even when accounting for established clinical parameters such as sex and isotype. These findings underscore the robustness and independence of the SenMayo gene signature as a predictor of overall survival in multiple myeloma. This signature provides clinically valuable insights into the role of cellular senescence in disease progression. LA - English DB - MTMT ER - TY - JOUR AU - Ungvári, Zoltán István AU - Fekete, Mónika AU - Lehoczki, Andrea Marianna AU - Munkácsy, Gyöngyi AU - Fekete, János Tibor AU - Zábó, Virág AU - Purebl, György AU - Varga, Péter AU - Ungvári, Anna Sára AU - Győrffy, Balázs TI - Inadequate sleep increases stroke risk: evidence from a comprehensive meta-analysis of incidence and mortality JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01593-x UR - https://m2.mtmt.hu/api/publication/35925785 ID - 35925785 N1 - * Megosztott szerzőség AB - The link between abnormal sleep duration and stroke outcomes remains contentious. This meta-analysis quantifies how both short and long sleep durations impact stroke incidence and mortality. A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, Embase, and Google Scholar up to November 1, 2024, to identify cohort studies evaluating sleep duration and stroke outcomes. Meta-analysis was performed using MetaAnalysisOnline.com and a random-effects model to estimate pooled hazard ratios (HRs). Results were visualized through Forest and Funnel plots. Analysis of 43 studies (35 on stroke incidence, 8 on mortality) revealed significant associations between sleep duration and stroke outcomes. Short sleep duration (≤ 5–6 h) was associated with increased stroke incidence (HR 1.29, 95% CI 1.19–1.40, p < 0.01) and modestly elevated mortality (HR 1.12, 95% CI 1.01–1.25, p = 0.03). Long sleep duration (> 8–9 h) demonstrated stronger associations with both increased stroke incidence (HR 1.46, 95% CI 1.33–1.60, p < 0.01) and mortality (HR 1.45, 95% CI 1.31–1.60, p < 0.01). Significant heterogeneity was observed in incidence studies ( I 2 = 74–75%), while mortality analyses showed moderate to low heterogeneity ( I 2 = 35–40%). This meta-analysis highlights a U-shaped association between sleep duration and stroke risk, with both short and long sleep durations linked to higher stroke incidence and mortality. These findings underscore the importance of balanced sleep duration as a modifiable risk factor in stroke prevention strategies and provide a foundation for the Semmelweis Study, a prospective workplace cohort investigating the role of modifiable lifestyle factors in unhealthy cerebrovascular and brain aging. LA - English DB - MTMT ER - TY - JOUR AU - Ungvári, Zoltán István AU - Fekete, Mónika AU - Varga, Péter AU - Fekete, János Tibor AU - Lehoczki, Andrea Marianna AU - Buda, Annamaria AU - Szappanos, Ágnes AU - Purebl, György AU - Ungvári, Anna Sára AU - Győrffy, Balázs TI - Imbalanced sleep increases mortality risk by 14–34%: a meta-analysis JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - in press PY - 2025 SN - 2509-2715 DO - 10.1007/s11357-025-01592-y UR - https://m2.mtmt.hu/api/publication/35912335 ID - 35912335 N1 - * Megosztott szerzőség AB - Sleep duration is a crucial factor influencing health outcomes, yet its relationship with mortality remains debated. In this meta-analysis, we aimed to investigate the association between short and long sleep duration and all-cause mortality in adults, including sex-specific differences. A systematic search was performed in multiple databases, including PubMed, Cochrane Central, and Web of Science, up to October 2024. Retrospective and prospective cohort studies involving adults with at least 1 year of follow-up and data on sleep duration and all-cause mortality were included. Hazard ratios were pooled using a random-effects model, with subgroup analyses performed based on sex and sleep duration categories. A total of 79 cohort studies were included, with data stratified by sex and categorized into short and long sleep durations. Short sleep duration (< 7 h per night) was associated with a 14% increase in mortality risk compared to the reference of 7–8 h, with a pooled hazard ratio of 1.14 (95% CI 1.10 to 1.18). Conversely, long sleep duration (≥ 9 h per night) was associated with a 34% higher risk of mortality, with a hazard ratio of 1.34 (95% CI 1.26 to 1.42). Sex-specific analyses indicated that both short and long sleep durations significantly elevated mortality risk in men and women, although the effect was more pronounced for long sleep duration in women. Both short and long sleep durations are associated with increased all-cause mortality, though the degree of risk varies by sex. These findings underscore the importance of considering optimal sleep duration in public health strategies aimed at enhancing longevity and highlight the need for sex-specific approaches in sleep health research. LA - English DB - MTMT ER - TY - JOUR AU - Callari, Maurizio AU - Dugo, Matteo AU - Barreca, Marco AU - Győrffy, Balázs AU - Galbardi, Barbara AU - Vigano, Lucia AU - Locatelli, Alberta AU - Dall’Ara, Chiara AU - Ferrarini, Marina AU - Bisagni, Giancarlo AU - Colleoni, Marco AU - Mansutti, Mauro AU - Zamagni, Claudio AU - Del Mastro, Lucia AU - Zambelli, Stefania AU - Frassoldati, Antonio AU - Biasi, Olivia AU - Pusztai, Lajos AU - Valagussa, Pinuccia AU - Viale, Giuseppe AU - Gianni, Luca AU - Bianchini, Giampaolo TI - Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies JF - NATURE COMMUNICATIONS J2 - NAT COMMUN VL - 16 PY - 2025 IS - 1 PG - 15 SN - 2041-1723 DO - 10.1038/s41467-025-57293-9 UR - https://m2.mtmt.hu/api/publication/35846040 ID - 35846040 N1 - Fondazione Michelangelo, Milan, Italy IRCCS San Raffaele Hospital, Milan, Italy Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy Dept. of Bioinformatics, Semmelweis University, Budapest, Hungary Dept. of Biophysics, Medical School, University of Pecs, Pecs, Hungary Cancer Biomarker Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, Budapest, Hungary AUSL – IRCCS, Reggio Emilia, Italy IEO, European Institute of Oncology, IRCCS, Milan, Italy Udine Academic Hospital, Udine, Italy IRCCS Azienda Ospedaliero Universitaria, Bologna, Italy Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, Università di Genova, Genoa, Italy Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, United States UniSR San Raffaele University, Milan, Italy Export Date: 25 March 2025; Correspondence Address: L. Gianni; Fondazione Michelangelo, Milan, Italy; email: luca.gianni@fondazionemichelangelo.org; G. Bianchini; IRCCS San Raffaele Hospital, Milan, Italy; email: bianchini.giampaolo@hsr.it LA - English DB - MTMT ER - TY - JOUR AU - Fekete, János Tibor AU - Győrffy, Balázs TI - MetaAnalysisOnline.com : an Online Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies JF - JOURNAL OF MEDICAL INTERNET RESEARCH J2 - J MED INTERNET RES VL - 27 PY - 2025 PG - 11 SN - 1438-8871 DO - 10.2196/64016 UR - https://m2.mtmt.hu/api/publication/35766983 ID - 35766983 N1 - Funding Agency and Grant Number: National Research, Development, and Innovation Office (PharmaLab) [RRF-2.3.1-21-2022-00015] Funding text: The 4.0 version of ChatGPT, developed by OpenAI, was used as a language tool to refine our writing and enhance the clarity of our work. This project was supported by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015) . A5 Genetics Ltd (Kutaso, Hungary) provided computational infrastructure for the study. AB - A meta-analysis is a quantitative, formal study design in epidemiology and clinical medicine that systematically integrates and quantitatively synthesizes findings from multiple independent studies. This approach not only enhances statistical power but also enables exploration of effects across diverse populations and helps resolve controversies arising from conflicting studies.We aimed to develop and implement a user-friendly tool for conducting meta-analyses, addressing the need for an accessible platform that simplifies the complex statistical procedures required for evidence synthesis while maintaining methodological rigor.The platform available at www.metaanalysisonline.com enables comprehensive meta-analyses through an intuitive web interface, requiring no programming expertise or command-line operations. The system accommodates diverse data types including binary (total and event numbers), continuous (mean and standard deviation), and time-to-event data (hazard rates with confidence intervals), while implementing both fixed-effect and random-effect models using established statistical approaches such as DerSimonian-Laird, Mantel-Haenszel, and inverse variance methods for effect size estimation and heterogeneity assessment.In addition to statistical tests, graphical representations including the forest plot, the funnel plot, and the Z-score plot can be drawn. A forest plot is highly effective in illustrating heterogeneity and pooled results. The risk of publication bias can be revealed by a funnel plot. A Z-score plot provides a visual assessment of whether more research is needed to establish a reliable conclusion. All the discussed models and visualization options are integrated into the registration-free online web portal. Leveraging metaanalysisonline.com's capabilities, we examined treatment-related adverse events in cancer patients receiving perioperative anti-PD-1 immunotherapy through a systematic review encompassing ten studies with 8,099 total participants. Meta-analysis revealed that anti-PD-1 therapy doubled the risk of adverse events (risk ratio: 2.15, 95% CI: 1.39-3.32), with significant between-study heterogeneity (I-square=95%) and publication bias detected through Egger's test (P=.015). While these findings suggest increased toxicity associated with anti-PD-1 treatment, the Z-score analysis indicated that additional studies are needed for definitive conclusions.In summary, the online tool aims to bridge the void for clinical and life science researchers by offering a user-friendly alternative for the swift and reproducible meta-analysis of clinical and epidemiological trials. LA - English DB - MTMT ER - TY - JOUR AU - Müller, Dalma AU - Győrffy, Balázs TI - EpigenPlot: An interactive web platform for DNA methylation-based biomarker and drug target discovery in colorectal cancer JF - BRITISH JOURNAL OF PHARMACOLOGY J2 - BR J PHARMACOL VL - 182 PY - 2025 IS - 7 SP - 1452 EP - 1465 PG - 14 SN - 0007-1188 DO - 10.1111/bph.17455 UR - https://m2.mtmt.hu/api/publication/35744061 ID - 35744061 N1 - Funding Agency and Grant Number: Semmelweis Momentum Program; National Research, Development, and Innovation Office [RRF-2.3.1-21-2022-00015]; ELIXIR Hungary () Funding text: This project was supported by the Semmelweis Momentum Program and by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015). A GPT-based AI grammar check was used to improve the English of the manuscript. The computational infrastructure of A5 Genetics Ltd (Kutaso, Hungary) was used for the study. The support of ELIXIR Hungary () is acknowledged. LA - English DB - MTMT ER -